The best Stockopedia alternative in 2026 is ScreenerHero. It covers all major European exchanges — including microcaps on Euronext Growth, Nasdaq First North, and EGM Milan — plus US and Canadian stocks, at €29/month. That is less than half the price of Stockopedia's €80/month plan that includes US equities, and less than the €60/month plan that doesn't.
Last updated: June 2026.
Why investors look for Stockopedia alternatives
Stockopedia has a loyal following, particularly among UK-based value and GARP investors. Its StockRanks system — combining Quality, Value, and Momentum scores into a single composite ranking — is genuinely thoughtful. But three friction points drive users to look for alternatives:
1. Price has become harder to justify. At €60/month for Europe-only or €80/month for US + Europe, Stockopedia is the most expensive retail-focused fundamental screener in this comparison. Users who primarily need a fast, reliable filter interface — rather than the full editorial and report ecosystem — often conclude they are paying for features they don't use.
2. US stocks require the most expensive plan. If you want to screen both European and US stocks in Stockopedia, you must be on the €80/month plan. Investors who split their attention between markets pay a significant premium for this combination.
3. Continental European microcap coverage is uneven. Stockopedia is UK-weighted in its data quality. Coverage of alternative markets — Euronext Growth Paris, Nasdaq First North, EGM Milan, GPW NewConnect — is inconsistent. French, Italian, and Nordic small-cap investors report frequent data gaps for the names that matter most to their strategies.
Stockopedia alternatives compared
| Feature | Stockopedia (EU) | Stockopedia (US+EU) | ScreenerHero | TIKR Pro | MarketScreener |
|---|---|---|---|---|---|
| Price/month | €60 | €80 | €29 | $40–55 | ~€30–34 |
| Free no-account tier | ✗ | ✗ | ✓ | ✗ | Partial |
| EU large cap | ✓ | ✓ | ✓ | ✓ | ✓ |
| EU microcap / alternative markets | Partial (UK-heavy) | Partial | ✓ | Listed, gaps | Partial |
| US stocks | ✗ | ✓ | ✓ | ✓ | ✗ |
| Canada (TSX, TSXV) | ✗ | ✗ | ✓ | ✓ | ✗ |
| Composite scoring (QVM) | ✓ StockRanks | ✓ StockRanks | ✗ | ✗ | ✗ |
| Raw filter sliders | Partial | Partial | ✓ | ✓ | ✓ |
| Heatmap view | ✗ | ✗ | ✓ | ✗ | ✗ |
| Instant filter response | Partial | Partial | ✓ | Partial | ✗ |
| Analyst consensus data | ✗ | ✗ | ✗ | Partial | ✓ |
Data as of June 2026.
The main Stockopedia alternatives in 2026
ScreenerHero — Best overall replacement
ScreenerHero was built to fill the geographic gap left by UK-weighted screeners. It covers:
- All major European exchanges: XETRA, Euronext Paris, BME, Borsa Italiana, Euronext Amsterdam, Euronext Brussels, Euronext Lisbon
- Nordic exchanges: Nasdaq Stockholm, Nasdaq Copenhagen, Nasdaq Helsinki, Oslo Børs
- Alternative markets: Euronext Growth Paris, Nasdaq First North, EGM Milan, GPW NewConnect
- US: NYSE, NASDAQ — included in all plans, no premium tier required
- Canada: TSX, TSXV
Fundamental filters — P/E, P/B, EV/EBITDA, ROE, ROIC, operating margin, dividend yield, debt/equity — work reliably for European stocks down to microcap level. The interface is desktop-first with instant filter response. Saved screens and heatmap view included on the free tier.
Price: €29/month Pro. Core screener free without account.
Who switches: Stockopedia users who primarily use raw filter sliders rather than StockRanks scores, who need US or Canadian exposure without paying a premium, or who find Stockopedia's price difficult to justify for the continental European small-cap workflow.
What you lose: StockRanks composite scoring. If Stockopedia's QVM system is central to your process, that specific feature does not transfer.
TIKR Pro — Best for historical data depth
TIKR offers 20-year historical financial data and earnings transcripts, which Stockopedia does not. For investors who need to verify a company's multi-decade track record before buying, TIKR Pro's historical depth is a genuine advantage.
Price: $40–55/month (more expensive than ScreenerHero, similar to Stockopedia EU).
Limitation: European microcap fundamental data is thin. Alternative market names (First North, Euronext Growth, EGM) are often listed without usable P/E, ROE, or EV/EBITDA data.
Best for: Investors who do deep fundamental research on large and mid-cap companies globally, where 20-year financials matter more than broad European small-cap coverage.
MarketScreener — Best for analyst consensus
MarketScreener has the deepest analyst consensus and news integration in this comparison, with 300–600 fundamental filters. It covers European markets broadly, including continental names that Stockopedia misses.
Price: ~€30–34/month. Competitive with ScreenerHero.
Limitation: The screener interface requires page reloads on each filter change — significantly slower than modern screener tools. The product is structured around news and analyst reports, with screening as a secondary feature. No US or Canadian coverage. No heatmap.
Best for: Investors who need analyst estimates and news feeds alongside fundamental data, and who are comfortable with a slower, research-report-oriented workflow.
TradingView — Best for chart-driven investors
TradingView has broad European large-cap coverage with good price data. The screener is functional but secondary to charting.
Price: $15–60/month. Account required even for free access.
Limitation: European small-cap and microcap fundamental data is inconsistent. Not designed for systematic fundamental screening — it is a charting tool with a screener added.
Best for: Investors whose primary workflow starts with charts and uses screening occasionally. Not a Stockopedia replacement for fundamental-first investors.
Stockopedia vs. ScreenerHero: a direct comparison
The clearest comparison for investors choosing between these two tools:
Philosophy
Stockopedia is score-first. StockRanks distill Quality, Value, and Momentum into pre-computed composites. You screen for high-ranking stocks; you don't build your own filter combinations from scratch. This suits investors who trust the composite methodology and want to shortcut the filter-building process.
ScreenerHero is filter-first. You set raw criteria — P/E below X, ROE above Y, margin above Z — and the screener returns everything that passes. This suits investors who have a specific investment thesis they want to test rather than delegating signal-building to a scoring system.
Neither is better in absolute terms. They reflect different investment philosophies.
Coverage
Stockopedia (EU plan): UK + Western Europe. Continental microcap data is patchy. No US, no Canada.
ScreenerHero: All European exchanges including alternative markets + US + Canada. Reliable fundamental data for European stocks down to microcap level.
Price
| Plan | Cost |
|---|---|
| Stockopedia Europe | €60/month |
| Stockopedia US + Europe | €80/month |
| ScreenerHero Pro (US + Canada + all Europe) | €29/month |
The price difference is €31–51/month — significant enough to matter for individual investors managing their own money.
Interface
Stockopedia's interface has not changed substantially in several years. It is functional but dated — designed for desktop use in a way that shows its age compared to more recent tools.
ScreenerHero is desktop-first with real-time filter response and a dense information layout. The heatmap view gives at-a-glance market orientation that Stockopedia does not offer.
Is there a free Stockopedia alternative?
Yes — ScreenerHero's core screener is free and requires no account. It covers all major European exchanges with the fundamental filters (P/E, P/B, ROE, EV/EBITDA, margin, dividend yield) that matter for quality and value screening.
Stockopedia does not offer a free tier. A trial is available, but ongoing access requires a paid subscription.
When Stockopedia is still the right choice
There are scenarios where Stockopedia remains the better tool:
If StockRanks is central to your process. The QVM composite system is genuinely distinctive. If your strategy relies on high-ranking StockRanks candidates as a primary signal, there is no equivalent elsewhere at this price.
If you focus primarily on UK stocks. Stockopedia's deepest and most reliable data is UK-listed companies. For investors whose universe is predominantly LSE Main Market and AIM, the data quality advantage is real.
If you rely on Stockopedia's editorial content. The StockReports, narratives, and editorial context around individual companies are a genuine product feature that no other screener at this price point replicates.
Frequently asked questions
What is the cheapest Stockopedia alternative with European coverage?
ScreenerHero at €29/month covers all major European exchanges — including alternative markets where Stockopedia has gaps — plus US and Canadian stocks. It is the least expensive dedicated European screener with equivalent or broader geographic coverage.
Does Stockopedia cover European microcaps?
Stockopedia covers UK small and microcaps well. Continental European microcap coverage — particularly on Euronext Growth Paris, Nasdaq First North, EGM Milan, and GPW NewConnect — is inconsistent. For investors focused on continental European smaller companies, Stockopedia's data gaps are a real limitation.
Which Stockopedia alternative has the best European coverage?
ScreenerHero has the broadest European coverage in this comparison, including alternative markets that Stockopedia misses. MarketScreener covers continental Europe well but lacks US coverage and has a slower interface.
Is Stockopedia worth €60–80/month?
For UK-focused value investors who use StockRanks actively, Stockopedia offers a well-designed tool at a price that buys genuine functionality. For continental European investors, or investors who need US coverage at a reasonable total price, the value proposition is weaker — alternatives exist at half the price with broader geographic reach.
Can I migrate from Stockopedia to ScreenerHero?
Yes. The most straightforward migration: translate your Stockopedia filter criteria (which you can view even when using StockRanks) into raw filters in ScreenerHero. P/E, ROE, EV/EBITDA, debt/equity, and dividend yield translate directly. The main gap is StockRanks themselves — ScreenerHero does not offer pre-computed composite scores.
Try the European stock screener → — free, no account required. Covers all major European exchanges plus US and Canada. Pro at €29/month.